192 related articles for article (PubMed ID: 9422561)
1. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study.
Kurnit KC; Nobre SP; Fellman BM; Iglesias DA; Lindemann K; Jhingran A; Eriksson AGZ; Ataseven B; Glaser GE; Mueller JJ; Westin SN; Soliman PT
Gynecol Oncol; 2022 Dec; 167(3):452-457. PubMed ID: 36243601
[TBL] [Abstract][Full Text] [Related]
3. High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome.
Viani GA; Patia BF; Pellizzon AC; De Melo MD; Novaes PE; Fogaroli RC; Conte MA; Salvajoli JV
Radiat Oncol; 2006 Aug; 1():24. PubMed ID: 16887018
[TBL] [Abstract][Full Text] [Related]
4. Effects of Adjuvant Radiation Plus Chemotherapy on Survival Outcomes in Stage III C Endometrial Cancer According to Histology: Analysis of Data from the Surveillance, Epidemiology, and End Results Database.
Kou J; Yan G; Xiao L; Wei N; Ren H; Xu J
Technol Cancer Res Treat; 2023; 22():15330338231208610. PubMed ID: 37926997
[No Abstract] [Full Text] [Related]
5. Treatment outcomes of patients with FIGO Stage I/II uterine cervical cancer treated with definitive radiotherapy: a multi-institutional retrospective research study.
Ariga T; Toita T; Kato S; Kazumoto T; Kubozono M; Tokumaru S; Eto H; Nishimura T; Niibe Y; Nakata K; Kaneyasu Y; Nonoshita T; Uno T; Ohno T; Iwata H; Harima Y; Wada H; Yoshida K; Gomi H; Numasaki H; Teshima T; Yamada S; Nakano T
J Radiat Res; 2015 Sep; 56(5):841-8. PubMed ID: 26109680
[TBL] [Abstract][Full Text] [Related]
6. Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?
Lefebvre M; Duchatelet M; El Hajj H; De Courrèges A; Wallet J; Bellier C; Le Tinier F; Le Deley MC; Martinez Gomez C; Leblanc E; Narducci F; Hudry D
Curr Oncol; 2023 Jan; 30(1):1174-1185. PubMed ID: 36661739
[TBL] [Abstract][Full Text] [Related]
7. High dose rate
Abtahi M; Gholami S; Jassim HH
Biomed Phys Eng Express; 2021 Aug; 7(5):. PubMed ID: 34375964
[No Abstract] [Full Text] [Related]
8. Partial-Length Treatment With Brachytherapy in Patients With Endometrial Cancer With High-Risk Features Is as Effective as Full-Length Vaginal Brachytherapy but With Reduced Toxicity.
Wernicke AG; Parashar B; Samuel E; Sabbas A; Gupta D; Caputo T
Pract Radiat Oncol; 2023; 13(5):e416-e422. PubMed ID: 37295725
[TBL] [Abstract][Full Text] [Related]
9. Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study.
Gao Y; Liu Z; Chen X; Luo W; Zhang L; Wang J
BMC Cancer; 2011 Oct; 11():439. PubMed ID: 21989202
[TBL] [Abstract][Full Text] [Related]
10. Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging.
Gultekin M; Guler OC; Yuce Sari S; Akkus Yildirim B; Onal C; Celik H; Yuce K; Ayhan A; Arik Z; Kose F; Altundag O; Zoto Mustafayev T; Atalar B; Bolukbasi Y; Yildiz F
J Obstet Gynaecol; 2021 Apr; 41(3):414-420. PubMed ID: 32347768
[TBL] [Abstract][Full Text] [Related]
11. Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline.
Harkenrider MM; Abu-Rustum N; Albuquerque K; Bradfield L; Bradley K; Dolinar E; Doll CM; Elshaikh M; Frick MA; Gehrig PA; Han K; Hathout L; Jones E; Klopp A; Mourtada F; Suneja G; Wright AA; Yashar C; Erickson BA
Pract Radiat Oncol; 2023; 13(1):41-65. PubMed ID: 36280107
[TBL] [Abstract][Full Text] [Related]
12. The impact of neo/adjuvant treatment choices on prognosis for surgically treated small-cell neuroendocrine carcinoma of the cervix.
Zhao D; Sun S; Yang Z; Wang P; Qiu H
Neoplasma; 2024 Feb; 71(1):70-76. PubMed ID: 38215035
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and treatment outcomes in surgically-staged non-invasive uterine clear cell carcinoma: a Turkish Gynecologic Oncology Group study.
Sarı ME; Meydanlı MM; Türkmen O; Cömert GK; Turan AT; Karalök A; Şahin H; Haberal A; Kocaman E; Akbayır Ö; Erdem B; Numanoğlu C; Güngördük K; Sancı M; Gökçü M; Özgül N; Salman MC; Boyraz G; Yüce K; Güngör T; Taşkın S; Altın D; Ortaç UF; Ayık HA; Şimşek T; Arvas M; Ayhan A
J Gynecol Oncol; 2017 Jul; 28(4):e49. PubMed ID: 28541637
[TBL] [Abstract][Full Text] [Related]
14. Isolated vaginal recurrence in women with stage I endometrial cancer.
Rios-Doria E; Cun HT; Filippova OT; Mueller JJ; Alektiar KM; Ellenson LH; Makker V; Lakhman Y; Leitao MM; Jhingran A; Soliman PT; Abu-Rustum NR
Gynecol Oncol; 2023 Dec; 179():9-15. PubMed ID: 37864854
[TBL] [Abstract][Full Text] [Related]
15. An unusual uterine papillary serous carcinoma with post therapy disseminating metastasis presenting as primary renal malignancy: a case report.
Liu KT; Chang YC; Lin YC; Chang JL
Ann Med Surg (Lond); 2024 Jan; 86(1):456-462. PubMed ID: 38222732
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in undifferentiated uterine sarcoma: a subanalysis of the SARCUT study.
Macuks R; Yildirim Y; Mancari R; Achimas-Cadariu P; Madhuri TK; Ortega E; Mallmann M; Zivanovic O; Zapardiel I;
Arch Gynecol Obstet; 2023 Sep; 308(3):981-988. PubMed ID: 37193821
[TBL] [Abstract][Full Text] [Related]
17. Brachytherapy and surgery versus surgery alone for IB2 (FIGO 2018) cervical cancers: A FRANCOGYN study.
Aissaoui O; Phalippou J; Cordoba A; Azais H; Ouldamer L; Bolze PA; Ballester M; Huchon C; Mimoun C; Akladios C; Lecointre L; Raimond E; Graesslin O; Carcopino X; Lavoué V; Bendifallah S; Touboul C; Dabi Y; Canlorbe G; Koskas M; Chauvet P; Collinet P; Kerbage Y
Eur J Obstet Gynecol Reprod Biol; 2023 Nov; 290():128-134. PubMed ID: 37788511
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers.
Lai TS; Francoeur A; Manrriquez E; Venkat P; Chang A; Douek M; Bahrami S; Raman SS; Memarzadeh S
Brachytherapy; 2024; 23(3):266-273. PubMed ID: 38453533
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes in borderline and locally advanced pancreatic cancer with the addition of low-dose-rate brachytherapy to standard of care therapy.
Taylor RJ; Matthews GJ; Aseltine RH; Fields EC
Brachytherapy; 2024; 23(3):355-359. PubMed ID: 38402046
[TBL] [Abstract][Full Text] [Related]
20. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
